Document Detail


Assessment of hormone refractory prostate cancer.
MedLine Citation:
PMID:  9111614     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To define guidelines for the assessment of treatment in patients with hormone-refractory prostate cancer (HRPC). METHODS: In the light of modern research, and taking new treatment options into account, the Committee essays to specify different categories of patients entering clinical trials, and to define response criteria and those endpoints that are relevant in phase III studies and in short-term follow-up. RESULTS: HRPC comprises a range of disease states with varying responsiveness to therapy and length of survival. Patients with progression as evaluated by increasing prostate-specific antigen (PSA) values alone have a more favorable prognosis than those presenting with increasing tumor spread. In the assessment of these patients, the modes of previous therapy and the kind of tumor progression must be taken into account. The benefit of treatment of HRPC is often modest. While duration of survival remains the main and ultimate endpoint, the means of measuring short-term responsiveness to therapy are limited. A minority of patients have measurable tumor lesions. Decrease of PSA or other biochemical tumor markers may indicate depression of the tumor activity, but is not always associated with prolongation of survival. A variety of new treatments in HRPC are being investigated. They affect measurable tumor parameters in different ways. CONCLUSIONS: When a new agent is to be tested, it is important to measure all possible parameters before deciding which particular ones are appropriate for future investigations of this agent. In symptomatic patients, evaluation of subjective parameters, for example, relief of pain or improvement of performance status, is often the most reliable measure of treatment effect. However, these parameters should be clearly defined.
Authors:
D Newling; S D Fosså; L Andersson; P A Abrahamsson; Y Aso; M A Eisenberger; S Khoury; J S Kozlowski; K Kelly; H Scher; B Hartley-Asp
Related Documents :
8470314 - Reevaluation of prostate biopsy after definitive radiation therapy.
17091254 - The significance of modified gleason grading of prostatic carcinoma in biopsy and radic...
17514654 - Immunotherapy with dendritic cells for prostate cancer.
12735514 - Selecting a secondary treatment.
16110134 - Tumor parameters, clinical and pathological responses, medical management, and survival...
14732884 - Guidelines for the management and treatment of low-grade gliomas.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Urology     Volume:  49     ISSN:  0090-4295     ISO Abbreviation:  Urology     Publication Date:  1997 Apr 
Date Detail:
Created Date:  1997-05-12     Completed Date:  1997-05-12     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  46-53     Citation Subset:  IM    
Affiliation:
Department of Urology, Academic Hospital, Free University, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Hormonal / therapeutic use*
Bone Neoplasms / secondary
Humans
Male
Palliative Care
Prognosis
Prostatic Neoplasms / drug therapy*,  mortality,  pathology
Survival Rate
Treatment Failure
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials.
Next Document:  Analysis and presentation. Clinical trials on prostate cancer.